Multidisciplinary panel publishes 30 consensus statements to improve communication and shared decision-making in neuroblastoma care WEST CONSHOHOCKEN:  SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that “Bridging the Gap: Establishing Consensus for Improving Neuroblastoma Diagnosis and Care Experiences for Patients and Caregivers” has been published in Pediatric […]

BRUSSELS, 1 July 2026: SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from […]

19 May 2026: SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire the exclusive development and commercialisation rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) […]